Cancer Diagnosis and Treatment: A New Paradigm for an Old Foe

Martin Lehr is the Co-founder and CEO of Context Therapeutics. Context is a publicly traded biotech company that is developing T cell engaging bispecific antibodies for solid tumors. The company has raised $195 million across private and public financings.

In addition, Mr. Lehr serves on the Boards of Praesidia Biologics and CureDuchenne Ventures. Previously, Martin was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. Prior to Osage, Martin conducted research at the Sloan Kettering Institute in DNA repair and at the Children’s Hospital of Philadelphia in thrombosis and hemostasis. Martin is a Director of BioBreak, a biotech executive peer networking group with over 2,500 active members across the United States, and an Advisory Board Member of Life Science Cares and Life Science Leader magazine.

Mr. Lehr holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania.

Register at https://kkbe.shulcloud.com/event/brotherhood-medical-zoom-program.html for the Zoom link.